The Resistant Starch Intervention for Cognitive Enhancement
The Resistant Starch Intervention for Cognitive Enhancement (RICE) in Individuals With High Genetic Risk
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Min Lou, PhD, MD
- Phone Number: 13958007213
- Email: lm99@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Second Affilated Hospital of Zhejiang University, School of Medicine
-
Contact:
- Min Lou, PhD, MD
- Phone Number: 13958007213
- Email: lm99@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥ 40 years
- meta-polygenic risk score (metaPRS) > 0.4
- Montreal Cognitive Assessment (MoCA) score ≤ 26
- Central obesity (waist circumference > 90 cm in males or > 80 cm in females) or body mass index (BMI) ≥ 28 kg/m²
- Written informed consent available
- Proficient in using smartphones
- Willingness to complete all assessments and participate in follow-up
Exclusion Criteria:
- Known hypersensitivity or allergy to resistant starch
- previously diagnosed dementia
- Suspected dementia after clinical assessment by study physician at screening visit
- Previous history of major head trauma and any intracranial surgery
- Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions
- Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement
- Severe loss of vision, hearing, or communicative ability
- Patients presenting a malignant disease with life expectancy < 3 years
- Participation in an ongoing investigational drug study
- The participant or a first-degree relative is currently participating in another clinical trial involving nutritional intervention.
Exit Criteria:
- Not meet the inclusion criteria
- For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator
- Any adverse or serious adverse events during the study period judged by Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: High-resistant starch foods intervention group
Participants in the intervention group will intake high resistant starch staple foods (achieving daily intake of ≥28g resistant starch)
|
Participants in the intervention group will intake high resistant starch staple foods (achieving daily intake of ≥28g resistant starch)
|
|
Placebo Comparator: Regular starch staple foods control group
Participants in the control group will intake isocaloric regular starch staple foods
|
Participants in the control group will intake isocaloric regular starch staple foods
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Primary Outcome
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Gut microbiota determined by measuring specific bacterial levels in the fecal samples
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Metabolite composition to measure the metabolite profiles in participants' faecal samples and serum samples
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Change in waist circumference
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Change in body mass index (BMI)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Changes in glymphatic function assessed by dispersion coefficient of periarterial and perivenous spaces on diffusion tensor imaging (DTI)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Changes in image markers (white matter hyperintensity, lacunes, microbleeds, perivascular spaces, brain atrophy, micro-infarcts) of CSVD assessed on MRI
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Changes in brain functional network connectivity assessed by resting state functional magnetic resonance imaging (fMRI)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Global cognitive function change assessed with Z-score of a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Working memory domain cognitive score change assessed with a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Executive function domain cognitive score change assessed with a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Language domain cognitive score change assessed with a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Visual motor speed domain cognitive score change assessed with a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Visual spatial function domain cognitive score change assessed with a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
|
Memory and recognition domain cognitive score change assessed with a digital cognitive assessment protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
Secondary Outcome
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RICE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.